Skip to main content
Home
Browse by Topic
Issues
Latest Issue
Issue Archive
Special Issues
Web Exclusives
Special Series
Conference Correspondent
ASH 2023 - CLL
Ovarian Cancer Overview
Multimedia
All Videos
Interview with the Innovators
Quick Quiz
Subscribe
Home
Browse by Topic
Issues
Latest Issue
Issue Archive
Special Issues
Web Exclusives
Special Series
Conference Correspondent
ASH 2023 - CLL
Ovarian Cancer Overview
Multimedia
All Videos
Interview with the Innovators
Quick Quiz
Subscribe
The Best Molecular Biomarkers Available for Informing Immunotherapy of Cancer
Video
,
ASCO Highlights
Videos
David Spigel, MD
Dr David Spigel talks about currently available and emerging biomarkers that predict the greatest sensitivity to immunotherapy, including his insight into PD-L1, MSI, and TMB.
Related Items
Efficacy and Safety of Brigimadlin (BI 907828) in Patients With Advanced BTC: Data From 2 Phase 1a/1b Dose-Escalation/Expansion Trials
March 2024 Vol 17, No 2
ASCO Highlights
Preliminary Results of a Real-World Study of the Safety and Efficacy of Surufatinib in BTC
March 2024 Vol 17, No 2
ASCO Highlights
Dostarlimab Elicits 100% Complete Response Rate in Cohort of Patients with dMMR Rectal Cancer
By
Patricia Stewart
TOP - July 2022 Vol 15, No 4
Rectal Cancer
,
ASCO Highlights
Ibrutinib Added to Standard-of-Care Therapy Improves Progression-Free Survival in Older Patients with MCL
By
William King
TOP - July 2022 Vol 15, No 4
ASCO Highlights